CorMedix Inc (CRMD) USD0.001

Sell:$7.66Buy:$7.69Price increased$0.34 (4.63%)

Prices delayed by at least 15 minutes
Sell:$7.66
Buy:$7.69
Change:Price increased$0.34 (4.63%)
Deal now
Prices delayed by at least 15 minutes
Sell:$7.66
Buy:$7.69
Change:Price increased$0.34 (4.63%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Key people

Joseph Todisco
Chairman of the Board, Chief Executive Officer
Susan Blum
Chief Financial Officer
Elizabeth Hurlburt
Chief Operating Officer
Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
Erin Mistry
Executive Vice President, Chief Commercial Officer
Matthew T. David
Chief Business Officer
Myron M. Kaplan
Independent Chairman of the Board
Janet M. Dillione
Independent Director
Gregory Scott Duncan
Independent Director
Alan William Dunton
Independent Director
Steven W. Lefkowitz
Independent Director
Click to see more

Key facts

  • Shares in issue
    78.79m
  • EPIC
    CRMD
  • ISIN
    US21900C3088
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $617.71m
  • Employees
    64
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.